Compositions that specifically bind to colorectal cells and methods of using the same
AssigneeThomas Jefferson University
InventorScott A. Waldman
Life of this patent
Estimating the term…
Loading patent…
AssigneeThomas Jefferson University
InventorScott A. Waldman
Estimating the term…
Conjugated compounds that comprise an ST receptor binding moiety and an active moiety that is an antisense molecule are disclosed. Pharmaceutical compositions which comprise conjugated compounds that comprise an ST receptor binding moiety and an active moiety that is an antisense molecule are disclosed including pharmaceutical compositions that have enteric formulations. Methods of treating an individual suspected of suffering from colorectal cancer and methods of preventing colorectal cancer are disclosed.
A conjugated compound comprising:
A method of treating an individual suspected of suffering from colorectal cancer comprising the steps of administering to said individual a therapeutically effective amount of a pharmaceutical composition comprising:
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
From bacteria: from Enterobacteriaceae , e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
The non-active ingredient being a modifying agent: the modifying agent being a protein, peptide or polyamino acid
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is…: the…
Organic compounds: peptides, e.g. proteins , carriers being peptides, polyamino acids, proteins
Term ended 5 Oct 2016 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
The present invention relates to conjugated compounds which comprise an St receptor ligand moiety conjugated to an active moiety which is an antisense molecule. ST receptor binding moieties bind to the ST receptor which is found on human colon cells. The invention relates to antisense compositions specifically targeted to colon cells. The invention relates to methods of treating and preventing colorectal tumors.
Colorectal cancer is the third most common neoplasm worldwide. The mortality rate of newly diagnosed large bowel cancer approaches 50% and there has been little improvement over the past 40 years. Most of this mortality reflects local, regional and distant metastases.
Surgery is the mainstay of treatment for colorectal cancer but recurrence is frequent. Colorectal cancer has proven resistant to chemotherapy, although limited success has been achieved using a combination of 5-fluorouracil and levamisole. Surgery has had the largest impact on survival and, in some patients with limited disease, achieves a cure. However, surgery removes bulk tumor, leaving behind microscopic residual disease which ultimately results in recrudescence.
As used herein, the terms "ST" and "native ST" are used interchangeably and are meant to refer to heat-stable toxin (ST) which is a peptide produced by E. col, as well as other organisms. STs are naturally occurring peptides which 1) are naturally produced by organisms, 2) bind to the ST receptor and 3) activate the signal cascade that mediates ST-induced diarrhea.
As used herein, the term "ST receptor" is meant to refer to the receptors found on colorectal cells, including local and metastasized colorectal cancer cells, which bind to ST. In normal human individuals, ST receptors are found exclusively in cells of intestine, in particular in cells in the duodenum, small intestine (jejunum and ileum), the large intestine, colon (cecum, ascending colon, transverse colon, descending colon and sigmoid colon) and rectum.
As used herein, the term "ST receptor ligand" is meant to refer to compounds which specifically bind to the ST receptor. ST is an ST receptor ligand. An ST receptor ligand may be a peptide or a non-peptide.